featured
Efficacy and Risk Stratification of JAK Inhibitors for Moderate to Severe Atopic Dermatitis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Dermatitis
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Efficacy and Risk Stratification of Janus Kinase Inhibitors in the Treatment of Moderate-to-Severe Atopic Dermatitis
Dermatitis 2023 Aug 01;[EPub Ahead of Print], S Narla, JI SilverbergFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.